The Synergy between Antibiotics and the Nanoparticle-Based Photodynamic Effect
Source abstract
Abstract
Antimicrobial resistance (AMR) is a growing global health concern, necessitating innovative strategies beyond the development of new antibiotics. Here, we employed NdYVO 4:Eu 3+ nanoparticles, which can persistently produce reactive oxygen species (ROS) after stopping the light, as a model of photodynamic nanoparticles and demonstrated that the photodynamic effect can serve as an adjuvant with antibiotics to effectively reduce their minimum inhibitory concentration. These preirradiated nanoparticles could penetrate the bacterial cell membrane, significantly enhancing the potency of antibiotics. We showed that the synergy effect could be attributed to disrupting crucial cellular processes by ROS, including damaging cell membrane proteins, interfering with energy supply, and inhibiting antibiotic metabolism. Our findings suggested that complementing the photodynamic effect might be a robust strategy to enhance antibiotic potency, providing an alternative antibacterial treatment paradigm.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Antibiotic Use and Resistance · Pharmaceutical and Antibiotic Environmental Impacts · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Lab of Metal Matrix Composites, School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, P. R. China
Shanghai Key Laboratory of Veterinary Biotechnology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai 200240, P. R. China
Funding
National Natural Science Foundation of China
References (30)
Show source-provided references
1. Finland M. · Bulletin of the New York Academy of Medicine · 1951 · 27 · 199
2. 10.1186/s13756-015-0091-210.1186/s13756-015-0091-2 ↗
3. 10.3389/bjbs.2023.1138710.3389/bjbs.2023.11387 ↗
4. 10.1177/204209861455491910.1177/2042098614554919 ↗
5. 10.2174/187407070201401010710.2174/1874070702014010107 ↗
6. O’Neill J. · 2014
7. 10.4137/PMC.S1445910.4137/PMC.S14459 ↗
8. 10.1186/1744-8603-9-5810.1186/1744-8603-9-58 ↗
9. 10.1016/j.addr.2021.11394110.1016/j.addr.2021.113941 ↗
10. 10.1016/j.mib.2016.06.00810.1016/j.mib.2016.06.008 ↗
11. 10.1016/1011-1344(92)85104-310.1016/1011-1344(92)85104-3 ↗
12. 10.2174/15734070677743515810.2174/157340706777435158 ↗
13. 10.1016/j.jprot.2012.09.00710.1016/j.jprot.2012.09.007 ↗
14. 10.3390/ijms2122871610.3390/ijms21228716 ↗
15. 10.3390/gels1002011010.3390/gels10020110 ↗
16. 10.5978/islsm.27_18-RA-0110.5978/islsm.27_18-RA-01 ↗
17. 10.1007/s00239-019-09914-310.1007/s00239-019-09914-3 ↗
18. 10.1016/j.isci.2023.10837310.1016/j.isci.2023.108373 ↗
19. 10.3390/microorganisms1001006110.3390/microorganisms10010061 ↗
20. 10.1021/acsami.3c0517910.1021/acsami.3c05179 ↗
21. 10.1002/smll.20210416010.1002/smll.202104160 ↗
22. 10.1186/s12934-023-02122-110.1186/s12934-023-02122-1 ↗
23. 10.1007/978-3-319-06068-2_2310.1007/978-3-319-06068-2_23 ↗
24. 10.1016/j.colsurfb.2012.01.04610.1016/j.colsurfb.2012.01.046 ↗
25. 10.1128/AAC.01002-1010.1128/AAC.01002-10 ↗
26. 10.1002/adfm.20200872010.1002/adfm.202008720 ↗
27. Zango U. U. · MOJ. Drug Des. Develop. Ther · 2019 · 3 · 52
28. 10.1097/MRM.0b013e328358772710.1097/MRM.0b013e3283587727 ↗
29. 10.1007/s00018-004-4060-910.1007/s00018-004-4060-9 ↗
30. 10.1021/ja027704o10.1021/ja027704o ↗